Stockscreener 앱 받기
0.00
100.00%
-31.49
전일 마감가:
$31.49
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$3.85B
수익:
$596.96M
순이익/손실:
$221.32M
주가수익비율:
0.00
EPS:
1.7397
순현금흐름:
$208.13M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
0.00 | 3.85B | 596.96M | 221.32M | 208.13M | 1.7397 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Catalyst Pharmaceuticals, Inc. Revenue Breakdown – LS:A0LCUL - TradingView
CPRX|Catalyst Pharmaceuticals Inc|Price:31.490| - TradingKey
TradingKey - TradingKey
Catalyst Pharmaceuticals | 8-K/A: Current report (Amendment) - Moomoo
Catalyst Pharmaceuticals stock steadies as investors weigh latest earnings momentum - AD HOC NEWS
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) leaves Nasdaq after cash reserves reduce deal multiple - TechStock²
Catalyst Pharmaceuticals (NASDAQ:CPRX) departs Nasdaq as merger spread narrows to one cent - TechStock²
Catalyst Pharmaceuticals CLO Brian Elsbernd Sells 242,501 Shares Amid Angelini Pharma Acquisition Completion - Kalkine Media
Catalyst Pharmaceuticals (CPRX) director’s RSUs and options cashed out in merger - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) HR chief equity cashed out at $31.50 - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50 - Stock Titan
Angelini deal converts CATALYST PHARMACEUTICALS (NASDAQ: CPRX) officer equity to cash - Stock Titan
Catalyst Pharmaceuticals (CPRX) CCO exits equity in Angelini merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CEO equity converted to cash at $31.50 merger price - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO equity awards canceled for cash in Angelini merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CFO equity cancelled for cash in acquisition - Stock Titan
Catalyst Pharmaceuticals (CPRX) director’s RSUs and options cancelled in merger - Stock Titan
CATALYST PHARMACEUTICALS, INC. SEC Filing (Jul 17, 2026) - Stock Titan
Catalyst Pharmaceuticals, Inc. Files 8-K: Merger Agreement Details, Corporate Information & XBRL Data (2026) - Minichart
Angelini Pharma completes $4.1 billion Catalyst acquisition By Investing.com - Investing.com Australia
Italy’s Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst - 1470 & 100.3 WMBD
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst - Reuters
CATALYST PHARMACEUTICALS, INC. SEC Filing (Jul 15, 2026) - Stock Titan
Catalyst Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Angelini Pharma completes $4.1 billion Catalyst acquisition - Investing.com
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals - NTB Kommunikasjon
Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA - TechStock²
Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Growth and a High-Quality Technical Breakout Setup - ChartMill
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 1000 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 Health Care - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Composite 1500 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P TMI Index - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Global BMI Index - marketscreener.com
Angelini Pharma S.p.a. completed the acquisition of Catalyst Pharmaceuticals, Inc. from a group of shareholders. - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board - Sahm
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Holds Steady Near Support as Consolidation PersistsBearish Pattern Stocks - Bölüm Sonu Canavarı
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth - ChartMill
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger - Yahoo Finance
Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion - Pluang
Solaris Energy Infrastructure Set to Join S&P SmallCap 600 - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Proxy filing Summary - Quartr
Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary - Quartr
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst Pharma Shareholders Approve Angelini Merger Agreement - TipRanks
Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal - Stock Titan
Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary - Quartr
Catalyst Pharmaceuticals focuses on rare neuromuscular diseases as a specialized Nasdaq biotech - ad-hoc-news.de
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):